サンプル依頼リスト カート
  • English
  • Korean
表紙：アンデルセン・タウィル症候群の世界市場-2023年～2030年
市場調査レポート
商品コード
1345445

アンデルセン・タウィル症候群の世界市場-2023年～2030年

Global Andersen-Tawil Syndrome Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
アンデルセン・タウィル症候群の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

アンデルセン・タウィル症候群の世界市場は、2022年に19億米ドルに達し、2023-2030年の予測期間中にCAGR 7.4％で成長し、2030年には33億米ドルに達すると予測されています。

アンデルセン・タウィル症候群は、KCNJ2遺伝子の変異によって引き起こされる遺伝性疾患です。この遺伝子は、心筋細胞からカリウムイオンを輸送するイオンチャネルをコードしています。このイオンチャネルは骨格筋と心筋の正常な機能を維持するために不可欠です。通常、常染色体優性遺伝で親から受け継がれますが、新たな遺伝子変異により発症することもあります。具体的な症状や重症度は、同じ家族であっても人によって大きく異なります。

さらに、世界のアンデルセン・タウィル症候群市場は、アンデルセン・タウィル症候群の有病率の増加、希少疾患の治療薬を優先する政府の関心の高まり、治療を支援し認知度を高めるための団体の参入の増加、メドトロニック社、アボット・ラボラトリーズ社、ボストン・サイエンティフィック社、リバノバ社などの主要企業を有する主要企業による研究開発投資の増加など、さまざまな要因によって牽引されています。

ダイナミクス

アンデルセン・タウィル症候群の有病率の上昇

アンデルセン・タウィル症候群の有病率の増加は、予測期間中に市場が成長するのに役立つ重要な要因の1つです。アンデルセン・タウィル症候群（ATS）は、再発性の弛緩性筋力低下、心不整脈、特徴的な骨格と顔貌を伴うまれな常染色体優性疾患です。有病率は1,000,000人に0.8～1人と推定されていますが、特定の集団およびATS患者のサブグループからの有病率の報告により、実際の有病率はより高いと予想されます。ATSは表現型の多様性をもつまれな疾患であり、診断が困難です。罹患者は通常、1～2歳代に周期性麻痺または心臓症状のエピソードを呈します。

アンデルセン・タウィル症候群に関する進行中の臨床試験

アンデルセン・タウィル症候群に関する臨床試験が進行中であることは、ATSに対する潜在的な治療法の安全性と有効性を評価するのに役立つため、予測期間中に市場が成長するのに役立ちます。例えば、clinicaltrail.govによると、2022年9月にCentre Hospitalier Universitaire de Liege &University of Liegeは、Baby Detect Genomic Newborn Screeningに関する臨床研究を開始しました。この研究目的は、361の遺伝子に起因する126の治療可能な重症早期発症遺伝病を出生時に特定することです。これらの研究は基本的に、先天性副腎過形成、アンデルセン・タウィル症候群などを対象としています。したがって、この研究は2025年8月までに完了する予定です。

疾患に伴う合併症

疾患に伴う合併症は、市場のさらなる成長を妨げる要因の1つです。アンデルセン・タウィル症候群（ATS）には、主に脚の筋力低下や麻痺を引き起こす周期性麻痺など、さまざまな副作用があり、運動やストレス、暑い気候などが引き金となります。不整脈（異常な心臓のリズム）は、動悸、息切れ、失神を引き起こし、生命を脅かすことがあります。耳の位置が低い、目の間隔が広い、背が低いなどの異形性も、ATSの影響によるものです。これらの副作用は症状の重症度によって異なります。

このレポートの詳細サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • アンデルセン・タウィル症候群の有病率の上昇
      • アンデルセン・タウィル症候群に関する進行中の臨床試験
    • 抑制要因
      • 疾患に伴う合併症
    • 機会
      • 有効な治療法の入手可能性
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 疾患タイプ別

  • タイプ1
  • タイプ2

第8章 薬剤クラス別

  • 炭酸脱水酵素阻害薬
  • 抗不整脈薬
  • アミオダロン
  • フレカイニド
  • β遮断薬
  • アテノロール

第9章 投与経路別

  • 経口
  • 静脈内

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Merck
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Grevis Pharmaceuticals
  • Xeris Pharma
  • Novartis AG
  • Advanz Pharmaceuticals
  • Alembic Pharmaceuticals
  • Avet Pharmaceuticals
  • Hikma Pharmaceuticals
  • Micro Labs
  • Advagen Pharma

第14章 付録

目次
Product Code: PH6794

Overview

Global Andersen-Tawil Syndrome Market reached US$ 1.9 billion in 2022 and is expected to reach US$ 3.3 billion by 2030, growing with a CAGR of 7.4% during the forecast period 2023-2030.

Andersen-Tawil syndrome is an inherited disorder caused by a mutation in the KCNJ2 gene. This gene encodes an ion channel that transports potassium ions out of the cardiac muscle cells. This ion channel is essential for maintaining the normal functions of the skeletal and cardiac muscles. It is usually inherited from a parent in an autosomal dominant manner, but it can also occur due to a new genetic mutation. The specific symptoms and severity can vary greatly from one person to another, even among members of the same family.

Furthermore, the global Anderson-tawil syndrome market is driven by various factors like an increase in the prevalence of Andersen-tawil syndrome, increasing focus of the government to prioritize drugs for the treatment of rare diseases, increasing participation of organizations to support the treatment and to create awareness, rising research and development investments by the key players with having key players like Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, LivaNova Plc and others.

Dynamics

Rise in the Prevalence of Andersen Tawil Syndrome

The rise in the prevalence of Andersen Tawil Syndrome is one of the key factors that helps the market to grow during the forecast period. Andersen-Tawil syndrome (ATS) is a rare autosomal dominant disorder with recurrent flaccid muscle weakness, cardiac arrhythmias, and distinctive skeletal and facial features. The prevalence is estimated at 0.8-1 in 1,000,000, but the actual prevalence is expected to be higher due to the reported prevalence from a specific population and subgroup of ATS patients. ATS is a rare disease with broad phenotypic heterogeneity, making diagnosis challenging. Affected individuals typically present with episodes of periodic paralysis or cardiac symptoms in their first or second decade.

Ongoing Clinical Trials on Andersen Tawil Syndrome

The ongoing clinical trials on Andersen tawil syndrome help the market to grow during the forecast period, as clinical trials help assess the safety and effectiveness of potential treatments for ATS. For instance, according to clinicaltrail.gov in September 2022 Centre Hospitalier Universitaire de Liege & University of Liege started a clinical study on Baby Detect Genomic Newborn Screening on which the study objective is to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes. These studies are basically for the conditions with, Congenital Adrenal Hyperplasia, Andersen Tawil Syndrome and others. Hence, this study is estimated to be completed by August 2025.

Complications Associated with Disease

Complications Associated with Disease are one of the factors that hamper the market to grow market further. Hence Andersen Tawil syndrome (ATS) has various side effects, including periodic paralysis, which causes muscle weakness or paralysis, primarily in the legs, and can be triggered by exercise, stress, or hot weather. Arrhythmias, abnormal heart rhythms, can cause racing heartbeats, shortness of breath, or fainting, and can be life-threatening. Dysmorphic features, such as low-set ears, wide-spaced eyes, and short stature, can also result from ATS. These side effects vary depending on the severity of the condition.

Segment Analysis

The global Andersen-Tawil Syndrome market is segmented based on disease type, drug class, route of administration, distribution channel and region.

The Type 1 Segment from the Disease Type Segment Accounted For Approximately 41.7% of Andersen-Tawil Syndrome Share

The Type 1 segment from the disease type segment accounted for 41.7% and it is expected to be dominated during the forecast period. Type 1 Atrial Syndrome (ATS) is caused by mutations in the KCNJ11 gene, affecting 1 in 100,000 to 1 in 1 million people. Symptoms typically appear in childhood or adulthood, with severity varying from person to person.

For instance, in November 2022 Centro Nacional de Investigations Cardiovascular (CNIC) discovered the cause of arrhythmias and sudden death in the rare disease Andersen-Tawil syndrome type 1 (ATS1), which is caused by mutations affecting potassium channels that regulate electrical activity and the intracellular calcium cycle in cardiac and skeletal muscle.

The teams are led by Drs. Jose Jalife and Juan Antonio Bernal have discovered a previously unknown function of Kir2.1 channels, which control the essential electrical properties of excitable cells such as cardiac muscle, skeletal muscle, and neurons.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, due to the presence of major key players, advancement in treatment options, well-developed healthcare sector, rising prevalence of disease, and growing awareness towards health in this region. The improvement would be possible because of marketing examination instruments and because of existing players who have positively gotten comfortable with the market since the beginning.

For instance, in 2021, Novartis AG launched a new medication called KEVEYIS (dichlorphenamide) for the treatment of periodic paralysis, a symptom of Andersen-Tawil syndrome.

Competitive Landscape

The major global players in the market include: Merck, Grevis Pharmaceuticals, Xeris Pharma, Novartis AG, Advanz Pharmaceuticals, Alembic Pharmaceuticals, Avet Pharmaceuticals, Hikma Pharmaceuticals, Micro Labs, Advagen Pharma and among others.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the Andersen Tawil Syndrome market and vaccination for patients with neuromuscular disorders evolved during this pandemic in patients having these disorders. Skeletal muscle channelopathies encompass a group of rare genetic neuromuscular conditions, including myotonia congenita (MC), sodium channel myotonia (SCM), paramyotonia congenita (PMC), hypokalemic periodic paralysis (hypoPP), hyperkalemic periodic paralysis (hyperPP), and Andersen-Tawil syndrome (ATS). These conditions are characterized by episodic symptoms ranging from myotonia to periodic paralysis caused by the dysfunction of specific ion channels expressed in skeletal muscle.

By Disease Type

  • Type 1
  • Type 2

By Drug Class

  • Carbonic Anhydrate Inhibitors
    • Acetazolamide
    • Dichlorphenamide
  • Antiarrhythmic Drugs
  • Amiodarone
  • Flecainide
  • Beta-Blockers
  • Atenolol

By Route of Administration

  • Oral
  • Intravenous

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In May 2022 a French study, involving clinicians from the Institute, was carried out on 35 patients with ATS whose diagnosis was confirmed by molecular analysis. They were diagnosed and are being followed in Neuromuscular reference centres in France. The study included a retrospective clinical, histological, electroneuromyography (ENMG) and genetic analysis.
  • In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag with the aim of gaining the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of a 66% ownership interest in Trikaal Medi infotech, and AWACS, through its subsidiary ABCD Technologies LLP.

Why Purchase the Report?

  • To visualize the global Andersen-Tawil Syndrome market segmentation based on disease type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global Andersen-Tawil Syndrome market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The Global Andersen-Tawil Syndrome Market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Prevalence of Andersen Tawil Syndrome
      • 4.1.1.2. Ongoing Clinical Trials on Andersen Tawil Syndrome
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with Disease
    • 4.1.3. Opportunity
      • 4.1.3.1. Availability of Effective Treatments
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Type 1 *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Type 2

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Carbonic Anhydrate Inhibitors *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Antiarrhythmic Drugs
  • 8.4. Amiodarone
  • 8.5. Flecainide
  • 8.6. Beta-Blockers
  • 8.7. Atenolol

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Intravenous

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Merck*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Grevis Pharmaceuticals
  • 13.3. Xeris Pharma
  • 13.4. Novartis AG
  • 13.5. Advanz Pharmaceuticals
  • 13.6. Alembic Pharmaceuticals
  • 13.7. Avet Pharmaceuticals
  • 13.8. Hikma Pharmaceuticals
  • 13.9. Micro Labs
  • 13.10. Advagen Pharma

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us